Benzinga

Benzinga

Benzinga

jueves, agosto 20

Aclaris Therapeutics Inc

ACRSNASDAQ
Trade with Public
Trade with Public
$6.26
-0.18-2.72%
Últ. Act.: Aug 20, 10:48 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Aclaris Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aclaris Therapeutics (ACRS).

Price Target Range — 9 Quarters

Analyst Consensus — 13 Analysts

11Buy
2Hold
Consensus RatingOutperform# Analysts13Avg. Consensus PT$11Upside to Avg. PT+70.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 2, 2026LifeSci Capital—InitiateOutperform$13
May 5, 2026Piper SandlerBiren AminPT RaiseOverweight$7→$11
More with Benzinga EdgeGet Access

Analyst Ratings News

This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday

Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two Interactive.
Avi Kapoor

PRO
Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
Benzinga Newsdesk

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Citations for AMAT, BMEA, ACRS, KALU, SION.
Avi Kapoor

PRO
Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $12.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10

Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and raises the price target from $8 to $10.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10

Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform rating and announces Price Target of $10.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved